Phapros’ Partnership Fund Rp.1.8 Billion Bisnis Indonesia,, 2005-01-06
This year, PT Phapros Tbk will allocate a loan worth Rp.1.8 billion for the partnership programme with small businesses and cooperatives. The interest will vary from 6 percent to 12 percent per year from income. The payments could be done in 24 months. For the past 8 years, Phapros has recorded in loaning similar type loans to small businesses and cooperatives worth a total of Rp.3.4 billion. Up to this point, only Rp.200 million worth in payment is having trouble being returned.
Phapros Develops Herbal Medicine www.suaramerdeka.com, 2004-03-27
Due to high prices of raw materials for chemical medicines, PT Phapros has started to develop herbal medicine for the regional market. Since 90 percent of the raw material for chemical medicines have to be imported, manufacturing herbal medicines, which have lower side effect, is a much feasible option. Phapros started producing herbal medicines under the name of Agromed in 2001. Phapros, one of the largest pharmaceutical companies in Indonesia, has co-operated with a number of domestic vendours to provide raw materials for herbal medicines and produce these medicines in accordance to modern standards and quality. The system has helped expand other business networks and also develop Indonesia’s potential as medicinal plants’ developer. Phapros products, Tensigard and X-gra, have acquired phytopharmaceutical registration and are two of the four drugs that passed the registration. The management has prepared a Rp.30 billion budget to improve production, research and human resource development facilities. In 2003, Phapros had a 44 percent growth, which was higher than the average growth of the pharmaceutical industry (13.5 percent).
Copyright & Disclaimer PT. Dataindo Inti Swakarsa makes no representation to any other person with regard to the completeness or accuracy of the data or information contained herein, and it accepts no responsibility and disclaims all liability (save for liability which cannot be lawfully disclaimed) for loss or damage whatsoever suffered or incurred by any other person resulting from the use of, or reliance upon, the features, functions, tools, data or information contained herein.Information provided is not financial product advice. This report contains general information only. It is not intended as financial product advice and must not be relied upon as such. You should consider obtaining independent advice tailored to your specific circumstances before making any financial decisions. Copyright in this publication is owned by PT. Dataindo Inti Swakarsa. The publication is sold on the basis that the purchaser agrees not to copy the material contained within it for other than the purchasers own purposes. In the event that the purchaser uses or quotes from the material in this publication - in papers, reports, or opinions prepared for any other person - it is agreed that it will be sourced to: PT. Dataindo Inti Swakarsa